CorreGene is developing many First-in-class TCR-T cell therapeutic products and soluble TCR-fusion proteins for the treatment of tumors, chronic infections and other indications, including the first cell therapy product targeting KRAS-G12 mutation in China and the world's first TCR-fusion protein therapy for the treatment of HPV infectious diseases. At present, two TCR-T products have launched Investigator Initiated Trials (IIT) program.
Winner's Prize of "Maker Beijing 2021 innovation and entrepreneurship competition"
